Endocannabinoids in synaptic plasticity and neuroprotection

Neuroscientist

Volumn 21, Issue 2, 2015, Pages 152-168

  Xu, Jian Yi ^a   Chen, Chu ^b  

^a ALBERTA HEALTH SERVICES   (Canada)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Alzheimer's disease; chronic traumatic encephalopathy; input timing dependent plasticity; long term depression of inhibitory synaptic transmission; monoacylglycerol lipase; PPAR

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; CALCIUM ION; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; METABOTROPIC RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BRAIN FUNCTION; CALCIUM CELL LEVEL; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPAL CA1 REGION; HUMAN; INTERNEURON; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PERFORANT NERVE TRACT; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC EFFICACY; SYNAPTIC TRANSMISSION; TRAUMATIC BRAIN INJURY; ANIMAL; BRAIN; BRAIN DISEASE; HIPPOCAMPUS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; BRAIN DISEASES; ENDOCANNABINOIDS; HIPPOCAMPUS; HUMANS; NEURONAL PLASTICITY; NEUROPROTECTION; PYRAMIDAL CELLS; SIGNAL TRANSDUCTION;

EID: 84924933470     PISSN: 10738584     EISSN: 10894098     Source Type: Journal    
DOI: 10.1177/1073858414524632     Document Type: Review

References (157)

1. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996 ; 91: 1585-614
2. Alger BE, Pitler TA. Retrograde signaling at GABAA-receptor synapses in the mammalian CNS. Trends Neurosci. 1995 ; 18: 333-40
3. Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol. 2002 ; 68: 247-86
4. Alger BE. Endocannabinoid signaling in neural plasticity. Curr Top Behav Neurosci. 2009 ; 1: 141-72
5. Amaral DG, Witter MP. The three-dimensional organization of the hippocampal formation: a review of anatomical data. Neuroscience. 1989 ; 31: 571-91
6. Andersen P, Bliss TV, Skrede KK. Lamellar organization of hippocampal pathways. Exp Brain Res. 1971 ; 13: 222-38
7. Arevalo-Martin A, Garcia-Ovejero D, Molina-Holgado E. The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury. Neurobiol Dis. 2010 ; 38: 304-12
8. Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgansberger W. Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci. 2004 ; 24: 9953-61
9. Basu J, Srinivas KV, Cheung SK, Taniguchi H, Huang ZJ, Siegelbaum SA. A cortico-hippocampal learning rule shapes inhibitory microcircuit activity to enhance hippocampal information flow. Neuron. 2013 ; 79: 1208-21
10. Bender VA, Bender KJ, Brasier DJ, Feldman DE. Two coincidence detectors for spike timing-dependent plasticity in somatosensory cortex. J Neurosci. 2006 ; 26: 4166-77
11. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci. 2003 ; 23: 11136-41
12. Bensinger ST, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. 2008 ; 454: 470-7
13. Bisogno T, Di Marzo V. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets. 2010 ; 9: 564-73
14. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol. 2007 ; 14: 1347-56
15. Blennow K, Hardy J, Zetterberg H. The neuropathology and neurobiology of traumatic brain injury. Neuron. 2012 ; 76: 886-99
16. Bliss TV, Gardner-Medwin AR. Long-lasting potentiation of synaptic transmission in the dentate area of the unanaestetized rabbit following stimulation of the perforant path. J Physiol. 1973 ; 232: 357-74
17. Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 1973 ; 232: 331-56
18. Bright JJ, Kanakasabai S, Chearwae W, Chakraborty S. PPAR regulation of inflammatory signaling in CNS diseases. PPAR Res. 2008 ; 2008: 1-12
19. Brun VH, Leutgeb S, Wu HQ, Schwarcz R, Witter MP, Moser EI. Impaired spatial representation in CA1 after lesion of direct input from entorhinal cortex. Neuron. 2008 ; 57: 290-302
20. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F. CB2 receptors in the brain: role in central immune function. Br J Pharmacol. 2008 ; 153: 240-51
21. Carlson G, Wang Y, Alger BE. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci. 2002 ; 5: 723-4
22. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012 ; 76: 70-81
23. Centonze D, Finazzi-Agrò A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci. 2007 ; 28: 180-7
24. Chen R, Zhang J, Wu Y, Wang D, Feng G, Tang YP. Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep. 2012 ; 2: 1329-39
25. Chen R, Zhang J, Fan N, Teng Z, Wu Y, Yang H. THC-caused synaptic and memory impairments are mediated through COX-2 signaling. Cell. 2013 ; 155: 1554-65
26. Chen X, Zhang J, Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons against-amyloid insults. Neuroscience. 2011 ; 178: 159-68
27. Chevaleyre V, Castillo PE. Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron. 2003 ; 38: 461-72
28. Chevaleyre V, Castillo PE. Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron. 2004 ; 43: 871-81
29. Chevaleyre V, Takahashi KA, Castillo PE. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci. 2006 ; 29: 37-76
30. Claiborne BJ, Amaral DG, Cowan WM. A light and electron microscopic analysis of the mossy fibers of the rat dentate gyrus. J Comp Neurol. 1986 ; 246: 435-58
31. Colbert CM, Levy WB. Long-term potentiation of perforant path synapses in hippocampal CA1 in vitro. Brain Res. 1993 ; 606: 87-91
32. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996 ; 384: 83-7
33. Dan Y, Poo MM. Spike timing-dependent plasticity of neural circuits. Neuron. 2004 ; 44: 23-30
34. Dardiotis E, Karanikas V, Paterakis K Agrawal A, ed. Rijeka, Croatia: InTech ; 2012: 23-38.
35. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol. 2002 ; 2: 748-59
36. Dekosky ST, Blennow K, Ikonomovic MD, Gandy S. Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol. 2013 ; 9: 192-200
37. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992 ; 258: 1946-9
38. Diana MA, Marty A. Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol. 2004 ; 142: 9-19
39. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 2000 ; 14: 1432-8
40. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A. 2002 ; 99: 10819-24
41. Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol. 2004 ; 66: 1260-4
42. Drew PD, Xu J, Storer PD, Chavis JA, Racke MK. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int. 2006 ; 49: 183-9
43. Du H, Chen X, Zhang J, Chen C. Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-I. Br J Pharmacol. 2011 ; 163: 1533-49
44. Dudman JT, Tsay D, Siegelbaum SA. A role for synaptic inputs at distal dendrites: instructive signals for hippocampal long-term plasticity. Neuron. 2007 ; 56: 866-79
45. Eichenbaum H. A cortical-hippocampal system for declarative memory. Nat Rev Neurosci. 2000 ; 1: 41-50
46. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron. 2006 ; 49: 67-79
47. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003 ; 83: 1017-66
48. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995 ; 232: 54-61
49. Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, Reisenberg M. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci. 2010 ; 30: 2017-24
50. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964 ; 86: 1646-7
51. Gerdeman GL, Ronesi J, Lovinger DM. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci. 2002 ; 5: 446-51
52. Gerrow K, Triller A. Synaptic stability and plasticity in a floating world. Curr Opin Neurobiol. 2010 ; 20: 631-9
53. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci. 2004 ; 20: 441-58
54. Hanus LO, Mechoulam R. Novel natural and synthetic ligands of the endocannabinoid system. Curr Med Chem. 2010 ; 17: 1341-59
55. Hashimotodani Y, Ohno-Shosaku T, Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist. 2007 ; 13: 127-37
56. Hasselmo ME, Schnell E. Laminar selectivity of the cholinergic suppression of synaptic transmission in rat hippocampal region CA1: computational modeling and brain slice physiology. J Neurosci. 1994 ; 14: 3898-914
57. Hein AM, O'Banion MK. Neuroinflammation and memory: the role of prostaglandins. Mol Neurobiol. 2009 ; 40: 15-32
58. Heinbockel T, Brager DH, Reich CG, Zhao J, Muralidharan S, Alger BE. Endocannabinoid signaling dynamics probed with optical tools. J Neurosci. 2005 ; 25: 9449-9459
59. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991 ; 11: 563-83
60. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990 ; 87: 1932-6
61. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 1990 ; 13: 420-3
62. Ishizuka N, Weber J, Amaral DG. Organization of intrahippocampal projections originating from CA3 pyramidal cells in the rat. J Comp Neurol. 1990 ; 295: 580-623
63. Ito M. Cerebellar long-term depression: characterization, signal transduction, and functional roles. Physiol Rev. 2001 ; 81: 1143-95
64. Izumi Y, Zorumski CF. Direct cortical inputs erase long-term potentiation at Schaffer collateral synapses. J Neurosci. 2008 ; 28: 9557-63
65. Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs. 2008 ; 22: 1-14
66. Jordan BD. The clinical spectrum of sport-related traumatic brain injury. Nat Rev Neurol. 2013 ; 9: 222-30
67. Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol. 2005 ; 68: 1196-202
68. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009 ; 89: 309-80
69. Kim J, Alger BE. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci. 2004 ; 7: 697-8
70. Kim J, Isokawa M, Ledent C, Alger BE. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci. 2002 ; 22: 10182-91
71. Kreitzer AC, Malenka RC. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci. 2005 ; 25: 10537-45
72. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature. 2007 ; 445: 643-7
73. Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 2001 ; 29: 717-27
74. Kummer MP, Heneka MT. PPARs in Alzheimer's disease. PPAR Res. 2008 ; 2008: 1-8
75. Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, Manzoni OJ. Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One. 2007 ; 2: e709
76. Lakis N, Corona RJ, Toshkezi G, Chin LS. Chronic traumatic encephalopathy - neuropathology in athletes and war veterans. Neurol Res. 2013 ; 35: 290-9
77. Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci. 2001 ; 14: 1827-32
78. Lenman A, Fowler CJ. Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system. Br J Pharmacol. 2007 ; 151: 1343-51
79. Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q. A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A. 2006 ; 103: 13345-50
80. Llano I, Leresche N, Marty A. Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron. 1991 ; 6: 565-74
81. Long JZ, Normura DK, Cravatt BF. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol. 2009a ; 16: 744-53
82. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009b ; 5: 37-44
83. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martínez A, Perez-Castillo A. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferatoractivated receptor activation. J Biol Chem. 2005 ; 280: 21453-62
84. Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci. 2005 ; 8: 1139-41
85. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003 ; 302: 84-8
86. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002 ; 418: 530-4
87. Mato S, Lafourcade M, Robbe D, Bakiri Y, Manzoni OJ. Role of the cyclic-AMP/PKA cascade and of P/Q-type Ca++ channels in endocannabinoid-mediated long-term depression in the nucleus accumbens. Neuropharmacology. 2008 ; 54: 87-94
88. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990 ; 346: 561-4
89. McKee AC, Stein TD, Nowinski CJ, Stern RA, Daneshvar DH, Alvarez VE. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013 ; 136: 43-64
90. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995 ; 50: 83-90
91. Morgan NH, Stanford IM, Woodhall GL. Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology. 2009 ; 57: 356-68
92. Mulder J, Zilberter M, Pasquaré SJ, Alpár A, Schulte G, Ferreira SG. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain. 2011 ; 134: 1041-60
93. Mulvihill MM, Nomura DK. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci. 2013 ; 92: 492-7
94. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993 ; 365: 61-5
95. Necela BM, Su W, Thomson EA. Toll-like receptor 4 mediates cross-talk between peroxisom proliferator-activated receptor A and nuclear factor- B in macrophages. Immunol. 2008 ; 125: 344-58
96. Nolan MF, Malleret G, Dudman JT, Buhl DL, Santoro B, Gibbs E. A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. Cell. 2004 ; 119: 719-32
97. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 2011 ; 334: 809-13
98. Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci. 2002 ; 22: 3864-72
99. Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist. 2012 ; 18: 119-32
100. Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery. 2005 ; 57: 128-34
101. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol. 2007 ; 152: 576-82
102. O'Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology. 2010 ; 215: 611-6
103. Otmakhova NA, Lewey J, Asrican B, Lisman JE. Inhibition of perforant path input to the CA1 region by serotonin and noradrenaline. J Neurophysiol. 2005 ; 94: 1413-22
104. Otmakhova NA, Lisman JE. Dopamine selectively inhibits the direct cortical pathway to the CA1 hippocampal region. J Neurosci. 1999 ; 19: 1437-45
105. Otmakhova NA, Lisman JE. Dopamine, serotonin, and noradrenaline strongly inhibit the direct perforant path-CA1 synaptic input, but have little effect on the Schaffer collateral input. Ann N Y Acad Sci. 2000 ; 911: 462-4
106. Pan B, Wang W, Long JZ, Sun D, Hillard CJ, Cravatt BF. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther. 2009 ; 331: 591-7
107. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001 ; 413: 527-31
108. Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab. 2005 ; 25: 477-84
109. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis. 2006 ; 22: 257-64
110. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010 ; 62: 588-631
111. Piro JR, Benjamin DI, Duerr JM, Pi Y, Gonzales C, Wood KM. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep. 2012 ; 1: 617-23
112. Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agrò A. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol. 2005 ; 57: 777-9
113. Pisani V, Moschella V, Bari M, Fezza F, Galati S, Bernardi G. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. Mov Disord. 2010 ; 25: 920-4
114. Pistis M, Melis M. From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr Med Chem. 2010 ; 17: 1450-67
115. Pitler TA, Alger BE. Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells. J Neurosci. 1992 ; 12: 4122-32
116. Pitler TA, Alger BE. Depolarization-induced suppression of GABAergic inhibition in rat hippocampal pyramidal cells: G protein involvement in a presynaptic mechanism. Neuron. 1994 ; 13: 1447-55
117. Racke MK, Drew PD. PPARs in neuroinflammation. PPAR Res. 2008 ; 2008: 638356
118. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005 ; 25: 1904-13
119. Remondes M, Schuman EM. Direct cortical input modulates plasticity and spiking in CA1 pyramidal neurons. Nature. 2002 ; 416: 736-40
120. Remondes M, Schuman EM. Role for a cortical input to hippocampal area CA1 in the consolidation of a long-term memory. Nature. 2004 ; 431: 699-703
121. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998 ; 391: 79-82
122. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A. 2002 ; 99: 8384-8
123. Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol. 2006 ; 70: 101-11
124. Ronesi J, Lovinger DM. Induction of striatal long-term synaptic depression by moderate frequency activation of cortical afferents in rat. J Physiol. 2005 ; 562: 245-56
125. Safo PK, Regehr WG. Endocannabinoids control the induction of cerebellar LTD. Neuron. 2005 ; 48: 647-59
126. Salmon JA, Higgs GA. Prostaglandins and leukotrienes as inflammatory mediators. Br Med Bull. 1987 ; 43: 285-96
127. Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord. 2005 ; 4: 677-84
128. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-I agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging. 2011 ; 32: 1626-33
129. Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G. Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol. 2011 ; 227: 128-35
130. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol. 2010 ; 160: 480-98
131. Shohami E, Cohen-Yeshurun A, Magid L, Algali M, Mechoulam R. Endocannabinoids and traumatic brain injury. Br J Pharmacol. 2011 ; 163: 1402-10
132. Sjostrom PJ, Turrigiano GG, Nelson SB. Neocortical LTD via coincident activation of presynaptic NMDA and cannabinoid receptors. Neuron. 2003 ; 39: 641-54
133. Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia?. Nat Rev Neurol. 2013 ; 9: 211-21
134. Solas M, Francis PT, Franco R, Ramirez MJ. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol Aging. 2013 ; 34: 805-8
135. Stella N. Endocannabinoid signaling in microglial cells. Neuropharmacol. 2009 ; 56: 244-53
136. Steward O, Scoville SA. Cells of origin of entorhinal cortical afferents to the hippocampus and fascia dentata of the rat. J Comp Neurol. 1976 ; 169: 347-70
137. Straiker A, Hu SS, Long JZ, Arnold A, Wager-Miller J, Cravatt BF. Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. Mol Pharmacol. 2009 ; 76: 1220-7
138. Sugiura T, Kobayashi Y, Oka S, Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids. 2002 ; 66: 173-92
139. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995 ; 215: 89-97
140. Tchantchou F, Zhang Y. Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury. J Neurotrauma. 2013 ; 30: 1-15
141. Tufekci KU, Meuwissen R, Genc S, Genc K. Inflammation in Parkinson's disease. Adv Protein Chem Struct Biol. 2012 ; 88: 69-132
142. van der Stelt M, Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med. 2005 ; 7: 37-50
143. van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 2005 ; 19: 1140-2
144. van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci. 2006 ; 63: 1410-24
145. Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat. 2009 ; 89: 112-9
146. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neurosci. 1994 ; 63: 637-52
147. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001 ; 410: 588-92
148. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002 ; 296: 678-82
149. Woodcock T, Morganti-Kossmann MC. The role of markers of inflammation in traumatic brain injury. Frontiers Neurol. 2013 ; 4: 1-18
150. Xu JY, Chen R, Zhang J, Chen C. Endocannabinoids differentially modulate synaptic plasticity in rat hippocampal CA1 pyramidal neurons. PLoS One. 2010 ; 5: e10306
151. Xu JY, Zhang J, Chen C. Long-lasting potentiation of hippocampal synaptic transmission by direct cortical input is mediated via endocannabinoids. J Physiol. 2012 ; 590: 2305-15
152. Yasuda H, Huang Y, Tsumoto T. Regulation of excitability and plasticity by endocannabinoids and PKA in developing hippocampus. Proc Natl Acad Sci U S A. 2008 ; 105: 3106-11
153. Yi J, Padalino DJ, Chin LS, Montenegro P, Cantu RC. Chronic traumatic encephalopathy. Curr Sports Med Rep. 2013 ; 12: 28-32
154. Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 2008 ; 1244: 164-72
155. Zetterberg H, Smith DH, Blennow K. Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol. 2013 ; 9: 201-10
156. Zhang J, Chen C. Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem. 2008 ; 283: 22601-11
157. Zhu PJ, Lovinger DM. Persistent synaptic activity produces long-lasting enhancement of endocannabinoid modulation and alters long-term synaptic plasticity. J Neurophysiol. 2007 ; 97: 4386-9